Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial

Paolo Tarantino shared a post on X:

“Can ADCs help prevent recurrence from breast cancer with less impact on patients’ quality of life than traditional chemotherapy?

Glad to share the final analysis of the ATEMPT phase 2 trial, just published in JCO.

Among 383 patients with stage I HER2+ breast cancer receiving adjuvant T-DM1, 5y iDFS was 97%, with only 3 (<1%) distant recurrences observed in the trial.

Patients with higher baseline HER2DX risk score had significantly higher risk of recurrence, further supporting validation of this biomarker to tailor treatments for HER2+ breast cancer.”

Guillermo Villacampa, Biostatistician in the Oncology Data Science Group (OdysSey) at Vall d’Hebron Institute of Oncology (VHIO), shared Paolo Tarantino’s post on X and added:

“Wonderful!

Congratulations Paolo Tarantino and Sara Tolaney on such nice work.

A pleasure to be part of the team.”

Source: Paolo Tarantino/X and Guillermo Villacampa/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.